Safety, efficacy and health-related quality of life (Hrqol) through 5 years of abatacept (Aba) treatment in patients with rheumatoid arthritis (Ra) and an inadequate response to anti-tumour necrosis factor (Tnf) therapy

Authors
Category Primary study
ConferenceZeitschrift fur Rheumatologie
Year 2010
This article has no abstract
Epistemonikos ID: c002a8b291f70052264973348238d702abd7d9b9
First added on: Apr 30, 2026